PAX8 expression variability in cerebellar hemangioblastoma: Case series and review of the literature

Daniel G. Eichberg, Simon Buttrick, Kyle White, Sakir Gultekin, Ricardo J. Komotar

Research output: Contribution to journalArticle

Abstract

Hemangioblastomas are benign tumors of undetermined origin, and account for up to 2.5% of all intracranial tumors. They may occur either sporadically or as a manifestation of von Hippel-Lindau (VHL) syndrome. Central nervous system (CNS) hemangioblastomas are pathologically diagnosed by gross and microscopic morphology, with further support of the diagnosis conferred by a characteristic immunohistochemistry profile including PAX8 negativity. Although renal hemangioblastomas have previously been reported to be PAX8 positive, CNS hemangioblastoma positive PAX8 expression has never been reported. We reviewed 11 cases of cerebellar hemangioblastoma from our institution over a 7-year period (2010 to 2017). Tissue was stained for PAX8 to determine immunohistochemical labeling. Of 11 reviewed cases of cerebellar hemangioblastoma, 7 exhibited PAX8 immunohistochemical expression. A review of the literature found no previously reported cases of positive PAX8 labeling in cerebellar hemangiomas. PAX8 negativity is not as specific for cerebellar hemangioblastoma as previously thought, and caution must be used when relying solely on a panel of PAX2, PAX8, and inhibin A for pathologic diagnosis.

Original languageEnglish (US)
Pages (from-to)477-481
Number of pages5
JournalApplied Immunohistochemistry and Molecular Morphology
Volume27
Issue number6
DOIs
StatePublished - Jul 1 2019

Fingerprint

Hemangioblastoma
Central Nervous System
von Hippel-Lindau Disease
Hemangioma
Neoplasms
Immunohistochemistry
Kidney

Keywords

  • brain tumor
  • hemangioblastoma
  • immunohistochemistry
  • PAX8
  • von Hippel-Lindau

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Medical Laboratory Technology

Cite this

PAX8 expression variability in cerebellar hemangioblastoma : Case series and review of the literature. / Eichberg, Daniel G.; Buttrick, Simon; White, Kyle; Gultekin, Sakir; Komotar, Ricardo J.

In: Applied Immunohistochemistry and Molecular Morphology, Vol. 27, No. 6, 01.07.2019, p. 477-481.

Research output: Contribution to journalArticle

Eichberg, Daniel G. ; Buttrick, Simon ; White, Kyle ; Gultekin, Sakir ; Komotar, Ricardo J. / PAX8 expression variability in cerebellar hemangioblastoma : Case series and review of the literature. In: Applied Immunohistochemistry and Molecular Morphology. 2019 ; Vol. 27, No. 6. pp. 477-481.
@article{e1f8ac4addcc45dbbad225f5eecfc114,
title = "PAX8 expression variability in cerebellar hemangioblastoma: Case series and review of the literature",
abstract = "Hemangioblastomas are benign tumors of undetermined origin, and account for up to 2.5{\%} of all intracranial tumors. They may occur either sporadically or as a manifestation of von Hippel-Lindau (VHL) syndrome. Central nervous system (CNS) hemangioblastomas are pathologically diagnosed by gross and microscopic morphology, with further support of the diagnosis conferred by a characteristic immunohistochemistry profile including PAX8 negativity. Although renal hemangioblastomas have previously been reported to be PAX8 positive, CNS hemangioblastoma positive PAX8 expression has never been reported. We reviewed 11 cases of cerebellar hemangioblastoma from our institution over a 7-year period (2010 to 2017). Tissue was stained for PAX8 to determine immunohistochemical labeling. Of 11 reviewed cases of cerebellar hemangioblastoma, 7 exhibited PAX8 immunohistochemical expression. A review of the literature found no previously reported cases of positive PAX8 labeling in cerebellar hemangiomas. PAX8 negativity is not as specific for cerebellar hemangioblastoma as previously thought, and caution must be used when relying solely on a panel of PAX2, PAX8, and inhibin A for pathologic diagnosis.",
keywords = "brain tumor, hemangioblastoma, immunohistochemistry, PAX8, von Hippel-Lindau",
author = "Eichberg, {Daniel G.} and Simon Buttrick and Kyle White and Sakir Gultekin and Komotar, {Ricardo J.}",
year = "2019",
month = "7",
day = "1",
doi = "10.1097/PAI.0000000000000649",
language = "English (US)",
volume = "27",
pages = "477--481",
journal = "Applied Immunohistochemistry",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - PAX8 expression variability in cerebellar hemangioblastoma

T2 - Case series and review of the literature

AU - Eichberg, Daniel G.

AU - Buttrick, Simon

AU - White, Kyle

AU - Gultekin, Sakir

AU - Komotar, Ricardo J.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Hemangioblastomas are benign tumors of undetermined origin, and account for up to 2.5% of all intracranial tumors. They may occur either sporadically or as a manifestation of von Hippel-Lindau (VHL) syndrome. Central nervous system (CNS) hemangioblastomas are pathologically diagnosed by gross and microscopic morphology, with further support of the diagnosis conferred by a characteristic immunohistochemistry profile including PAX8 negativity. Although renal hemangioblastomas have previously been reported to be PAX8 positive, CNS hemangioblastoma positive PAX8 expression has never been reported. We reviewed 11 cases of cerebellar hemangioblastoma from our institution over a 7-year period (2010 to 2017). Tissue was stained for PAX8 to determine immunohistochemical labeling. Of 11 reviewed cases of cerebellar hemangioblastoma, 7 exhibited PAX8 immunohistochemical expression. A review of the literature found no previously reported cases of positive PAX8 labeling in cerebellar hemangiomas. PAX8 negativity is not as specific for cerebellar hemangioblastoma as previously thought, and caution must be used when relying solely on a panel of PAX2, PAX8, and inhibin A for pathologic diagnosis.

AB - Hemangioblastomas are benign tumors of undetermined origin, and account for up to 2.5% of all intracranial tumors. They may occur either sporadically or as a manifestation of von Hippel-Lindau (VHL) syndrome. Central nervous system (CNS) hemangioblastomas are pathologically diagnosed by gross and microscopic morphology, with further support of the diagnosis conferred by a characteristic immunohistochemistry profile including PAX8 negativity. Although renal hemangioblastomas have previously been reported to be PAX8 positive, CNS hemangioblastoma positive PAX8 expression has never been reported. We reviewed 11 cases of cerebellar hemangioblastoma from our institution over a 7-year period (2010 to 2017). Tissue was stained for PAX8 to determine immunohistochemical labeling. Of 11 reviewed cases of cerebellar hemangioblastoma, 7 exhibited PAX8 immunohistochemical expression. A review of the literature found no previously reported cases of positive PAX8 labeling in cerebellar hemangiomas. PAX8 negativity is not as specific for cerebellar hemangioblastoma as previously thought, and caution must be used when relying solely on a panel of PAX2, PAX8, and inhibin A for pathologic diagnosis.

KW - brain tumor

KW - hemangioblastoma

KW - immunohistochemistry

KW - PAX8

KW - von Hippel-Lindau

UR - http://www.scopus.com/inward/record.url?scp=85069826528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069826528&partnerID=8YFLogxK

U2 - 10.1097/PAI.0000000000000649

DO - 10.1097/PAI.0000000000000649

M3 - Article

C2 - 29629948

AN - SCOPUS:85069826528

VL - 27

SP - 477

EP - 481

JO - Applied Immunohistochemistry

JF - Applied Immunohistochemistry

SN - 1541-2016

IS - 6

ER -